LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Listă Acțiuni・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Închisă

SectorSănătate

67.34 3.11

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

64.25

Maxim

68.33

Indicatori cheie
By Trading Economics
Venit	24M -167M
Vânzări	40M 195M
EPS	-0.84
Marjă de profit	-85.626
Angajați	834
EBITDA	75M -105M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+63.85% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-573M 13B
Deschiderea anterioară	64.23
Închiderea anterioară	67.34

Sentimentul știrilor

By Acuity

43%

57%

139 / 344 Clasament în Healthcare

Bridgebio Pharma Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 iun. 2026, 21:51 UTC

Principalele dinamici ale pieței

Merlin Shares Rally After Defense Department's Design Review Wraps

4 iun. 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 iun. 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 iun. 2026, 23:42 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 iun. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia to Enter Trading Halt

4 iun. 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 iun. 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 iun. 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 20:44 UTC

Achiziții, Fuziuni, Preluări

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 iun. 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 iun. 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 iun. 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 iun. 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 iun. 2026, 18:47 UTC

Achiziții, Fuziuni, Preluări

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 iun. 2026, 18:38 UTC

Câștiguri

Money Quote: Tech Weakness in Context -- WSJ

4 iun. 2026, 18:24 UTC

Câștiguri

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 iun. 2026, 16:58 UTC

Câștiguri

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 iun. 2026, 16:38 UTC

Câștiguri

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 iun. 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 iun. 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 iun. 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparație

Modificare preț

Bridgebio Pharma Inc Așteptări

Obiectiv de preț

By TipRanks

63.85% sus

Prognoză pe 12 luni

Medie 107.29 USD 63.85%

Maxim 157 USD

Minim 82 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBridgebio Pharma Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor Bridgebio Pharma Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

139 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.